Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CLDX Jul 2022 31.000 call

OPR - OPR Delayed Price. Currency in USD
Add to watchlist
0.2000-5.5000 (-96.49%)
At close: 03:48PM EDT
Advertisement
Full screen
Previous Close5.7000
Open1.0000
Bid0.0000
Ask0.2000
Strike31.00
Expire Date2022-07-15
Day's Range0.2000 - 1.0000
Contract RangeN/A
Volume2
Open Interest167
  • Investor's Business Daily

    Celldex Therapeutics Skids As It Takes On A Blockbuster Roche, Novartis Drug

    Celldex took aim at Roche and Novartis' blockbuster hives drug on Friday with a small study that showed promise — but CLDX stock tumbled.

  • Benzinga

    Celldex's Barzolvolimab Shows Rapid, Durable Responses In Early Urticaria Study

    Celldex Therapeutics Inc (NASDAQ: CLDX) announced interim data from Phase 1b trial of barzolvolimab in chronic spontaneous urticaria (CSU) refractory to antihistamines. CSU is characterized by the occurrence of hives or weals for six weeks or longer without identifiable specific triggers or causes. Data show that multiple doses of barzolvolimab resulted in dose-dependent decreases in itch and hives, with a mean UAS7 reduction of 66.6% in the 1.5 mg/kg dose group (n=8) at week 12 and 75.1% in 3.0

  • GlobeNewswire

    Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022

    -Rapid, profound and durable responses across multiple dosing groups with favorable safety profile--Mean reduction from baseline in urticaria activity (UAS7) of 66.6% in 1.5 mg/kg dose group at week 12 and 75.1% at week 8 in the 3 mg/kg dose group (reflects one dose; ongoing)--Complete response (UAS7=0) of 57.1% in 1.5 mg/kg dose group at week 12 and 44.4% at 8 weeks in 3 mg/kg dose group (reflects one dose; ongoing)--42% of patients treated with barzolvolimab had prior omalizumab and had simila

Advertisement
Advertisement